E
Eriko Aotani
Researcher at Kitasato University
Publications - 17
Citations - 389
Eriko Aotani is an academic researcher from Kitasato University. The author has contributed to research in topics: Carboplatin & Clinical trial. The author has an hindex of 9, co-authored 17 publications receiving 323 citations.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial
Toru Sugiyama,Aikou Okamoto,Takayuki Enomoto,Tetsutaro Hamano,Eriko Aotani,Yasuhisa Terao,Nao Suzuki,Mikio Mikami,Nobuo Yaegashi,Kiyoko Kato,Hiroyuki Yoshikawa,Yoshihito Yokoyama,Hiroshi Tanabe,Koji Nishino,Hiroyuki Nomura,Jae Weon Kim,Byoung-Gie Kim,Byoung-Gie Kim,Sandro Pignata,Jérôme Alexandre,John Green,Seiji Isonishi,Fumitoshi Terauchi,Keiichi Fujiwara,Daisuke Aoki +24 more
TL;DR: No significant survival benefit was found for CPT-P in patients with CCC, and both regimens were well tolerated, but the toxicity profiles differed significantly.
Journal ArticleDOI
Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—A Sankai Gynecology Study Group (SGSG) study
Yasunari Miyagi,Keiichi Fujiwara,Junzo Kigawa,Hiroaki Itamochi,Shoji Nagao,Eriko Aotani,Naoki Terakawa,Ichiro Kohno +7 more
TL;DR: The present pharmacological analysis suggests that intraperitoneal infusion of carboplatin is feasible not only as an intra peritoneal regional therapy but also as a more reasonable route for systemic chemotherapy.
Journal ArticleDOI
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine King,Martin R. Stockler,Rachel O'Connell,Luke Buizen,Florence Joly,Anne Lanceley,Felix Hilpert,Aikou Okamoto,Aikou Okamoto,Eriko Aotani,Jane Bryce,Paul Donnellan,Amit M. Oza,Elisabeth Åvall-Lundqvist,Elisabeth Åvall-Lundqvist,Jonathan S. Berek,Jalid Sehouli,A Feeney,Dominique Berton-Rigaud,Daniel S.J. Costa,Daniel S.J. Costa,Michael Friedlander +21 more
TL;DR: The MOSTv2 validly quantifies patient-reported symptom burden, adverse effects, and symptom benefit in ROC, and as such is fit-for-purpose for clinical trials of palliative chemotherapy in R OC.
Journal ArticleDOI
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.
Keiichi Fujiwara,Eriko Aotani,Tetsutaro Hamano,Shoji Nagao,Hiroyuki Yoshikawa,Toru Sugiyama,Junzo Kigawa,Daisuke Aoki,Noriyuki Katsumata,Masahiro Takeuchi,Mitsuaki Suzuki +10 more
TL;DR: The purpose of this trial is to prove the superiority of intraperitoneal administration of carboplatin over intravenous administration, primary endpoint is progression-free survival and secondary endpoints include overall survival, quality of life assessment and cost-benefit.
Journal ArticleDOI
Difference of carboplatin clearance estimated by the Cockroft–Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula
Shoji Nagao,Keiichi Fujiwara,Noriaki Imafuku,Kagawa R,Y. Kozuka,Takashi Oda,Maehata K,H. Ishikawa,H. Koike,Eriko Aotani,Ichiro Kohno +10 more
TL;DR: Estimates of carboplatin clearance calculated by the Jelliffe formula tend to have greater positive bias compared to the other four formulae, particularly when the BSA of the patient is small.